.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The VIBRANT phase 3 randomized trial evaluated intravitreal aflibercept for macular edema following branch retinal vein occlusion (BRVO), comparing it with grid laser photocoagulation. The trial showed clinically meaningful visual benefits with aflibercept, helping establish anti-VEGF therapy as a major treatment strategy for BRVO-associated macular edema. The study is relevant to retina practice because BRVO management often requires decisions about injection frequency, rescue therapy, and expectations for visual recovery. The evidence also illustrates the evolution from laser-based treatment toward intravitreal anti-VEGF approaches. For HCPs, the practical message is to recognize the treatable nature of macular edema secondary to BRVO and to use OCT and visual acuity together when monitoring response. The timing of treatment matters, and contemporary data continue to support early control of edema rather than allowing prolonged retinal thickening and photoreceptor disruption. In real-world practice, treatment plans must also account for systemic vascular risk factors, recurrence, adherence, and the patient's ability to return for serial injections and imaging.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The VIBRANT phase 3 randomized trial evaluated intravitreal aflibercept for macular edema following branch retinal vein occlusion (BRVO), comparing it with grid laser photocoagulation. The trial showed clinically meaningful visual benefits with aflibercept, helping establish anti-VEGF therapy as a major treatment strategy for BRVO-associated macular edema. The study is relevant to retina practice because BRVO management often requires decisions about injection frequency, rescue therapy, and expectations for visual recovery. The evidence also illustrates the evolution from laser-based treatment toward intravitreal anti-VEGF approaches. For HCPs, the practical message is to recognize the treatable nature of macular edema secondary to BRVO and to use OCT and visual acuity together when monitoring response. The timing of treatment matters, and contemporary data continue to support early control of edema rather than allowing prolonged retinal thickening and photoreceptor disruption. In real-world practice, treatment plans must also account for systemic vascular risk factors, recurrence, adherence, and the patient's ability to return for serial injections and imaging.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
